1
|
Amico AL, Fang R, Raoul A, Wroblewski K, Nielsen S, Weipert C, Abe H, Sheth D, Romero I, Kulkarni K, Schacht D, Patrick-Miller L, Verp M, Bradbury AR, Hlubocky F, Olopade OI. Abstract P5-19-04: Psychosocial impact of a multi-modality surveillance program for women at high-risk for breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-19-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To evaluate the psychosocial impact of semi-annual dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) screening in women at high-risk for breast cancer.
Background: For women with BRCA1 and BRCA2 mutations and/or a personal or family history of breast cancer, annual breast MRI has shown improved sensitivity and cancer detection compared to mammography. However, MRI's heightened sensitivity may lead to increased: false positives requiring additional follow-up biopsy/imaging; iatrogenic risk; and psychosocial distress, which all may negatively impact women's overall health-related quality of life.
Methods: Between 2004 and 2016, we assembled a prospective cohort of high-risk women undergoing semi-annual DCE-MRI and annual mammography. We reviewed a subset of this group. Participants completed psychosocial assessments at baseline and 6-month visits using the following measures: coping (MBSS); state/trait anxiety (STAI-S/T); depression (BDI-II); risk perception; and mental health (SF-36). Participants were classified according to Monitor or Blunter coping style. Mixed-effects logistic regressions models examined effects of demographics on psychosocial changes over time.
Results: 295 women were recruited to the study; 44% of the study participants had pathogenic mutations in BRCA1 or BRCA2 genes. 232 of 295 enrolled participants (78.6%) completed psychosocial assessments. For the total population: median age 44y (range: 21-73), 71% ≥college/post-graduate education; 84% Caucasian; 8% African American; 2% Latino; 99% with health insurance; 72% annual income of >$60,000. One third of women had a personal cancer history. Participants were evenly split between baseline Monitoring and Blunting coping style (49% and 51%, respectively). No significant differences were found between demographics (age, race, income, mutation, cancer type, cancer history) or psychosocial factors (baseline trait anxiety (p =0.64), depression (p =0.65), SF36 global health (p=0.66). After adjusting for education, race, cancer history and coping, women with ≥$60,000 income had lower trait anxiety (p<0.000) and greater mental health (p<0.001) than those with <$60,000 income. Over time, change in trait anxiety varied by coping (p=0.0006): Blunters did not experience significant changes in trait anxiety (p=0.072) while Monitors had significant diminished trait anxiety over time (p<0.001). For depression, women with ≥$60,000 income and college educated had lower BDI-II depression (p<0.000). Yet, women with a cancer history had significantly greater BDH-II depression (p= 0.048). Mental health over time varied by race as non-whites had greater gains in mental health (p=0.001) over time than whites (p=0.03).
Conclusion: Semi-annual DCE-MRI did not cause a significantly elevated state anxiety or depression, nor was there a significant decline in mental health over time for groups regardless of cancer history and genetic mutation status. Coping style may have an impact on psychosocial outcomes for those undergoing heightened surveillance over time.
Citation Format: Amico AL, Fang R, Raoul A, Wroblewski K, Nielsen S, Weipert C, Abe H, Sheth D, Romero I, Kulkarni K, Schacht D, Patrick-Miller L, Verp M, Bradbury AR, Hlubocky F, Olopade OI. Psychosocial impact of a multi-modality surveillance program for women at high-risk for breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-19-04.
Collapse
Affiliation(s)
- AL Amico
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - R Fang
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - A Raoul
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - K Wroblewski
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - S Nielsen
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - C Weipert
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - H Abe
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - D Sheth
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - I Romero
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - K Kulkarni
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - D Schacht
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - L Patrick-Miller
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - M Verp
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - AR Bradbury
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - F Hlubocky
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| | - OI Olopade
- The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Independent Contractor
| |
Collapse
|
2
|
Bayne LJ, Nivar I, Goodspeed B, Wileyto P, Savage J, Shih NNC, Feldman MD, Edwards J, Clark AS, Fox KR, Matro JM, Domchek SM, Bradbury AR, Shah PD, Chislock EM, Belka GK, Wang J, Amaravadi R, Chodosh LA, DeMichele AM. Abstract OT2-07-09: Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-07-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Recurrent breast cancers arise from minimal residual disease (MRD): the pool of disseminated and circulating tumor cells (DTCs and CTCs) that survive in their host following treatment of primary breast cancer. Detection of DTCs in the bone marrow (BM) after treatment is strongly associated with an increased risk of recurrence. Through the analysis of novel genetically-engineered mouse models, we have generated a substantial body of evidence that autophagy and mTOR signaling play key roles in the survival of DTCs. Moreover, administration of agents that block these pathways in mice harboring MRD reduces DTC burden and concomitantly reduces tumor recurrence, providing the rationale for translating these findings to patients (pts).
Trial Design:
The PENN-SURMOUNT screening study uses a clinically validated IHC assay (DTC-IHC) to identify at-risk pts who harbor DTCs. DTC+ pts are eligible for enrollment on the CLEVER trial, which will determine the feasibility, safety and efficacy of administering hydroxychloroquine (HCQ) and/or everolimus (EVE) in DTC+ patients to target MRD and prevent recurrence. PENN-SURMOUNT is single center, prospective cohort study of pts who have completed therapy for primary breast cancer, are within 5 yrs of diagnosis and are at increased risk for relapse by virtue of nodal positivity, triple negative disease, ER+/Oncotype DX RS ≥ 25, or residual disease after neoadjuvant therapy. Pts undergo screening BM aspirate to test for DTCs following completion of adjuvant chemo and radiotherapy. The primary objective of the study is to determine the incidence and frequency of MRD in pts who have completed primary treatment for breast cancer and to ascertain eligibility for the CLEVER recurrence prevention trial.
CLEVER is a randomized, controlled, open label phase II pilot trial. Target enrollment is 60 pts, with 15 pts allocated to each of 4 treatment arms: HCQ (600 mg BID), EVE (10mg daily), combination HCQ/EVE, or control/observation. A cycle is 28 days of continuous dosing. After a 3-month observation period, control pts will be offered HCQ/EVE therapy for 6 cycles; thus, the control group is actually a delayed treatment group and all pts will receive treatment. Pts who demonstrate persistent DTCs after 6 cycles will continue on combination therapy for an additional 6 cycles. The primary endpoint is feasibility of administering HCQ, EVE or the combination in this population. Secondary objectives include safety, efficacy (DTC reduction), and 3-year RFS. The principal translational objective is to assess the utility of a novel DTC assay, "DTC-Flow", for more sensitive detection and response to study therapy, compared to DTC-IHC. Additional translational objectives include determining whether patient DTCs, CTCs, and cell-free circulating plasma tumor DNA (ptDNA) biologically reflect the primary tumor and predict response.
As of 5/23/17, 58 patients have been enrolled to PENN SURMOUNT, with a DTC-positivity rate of 22.6%; CLEVER opened in 2/2017; 11 patients are currently enrolled. Contact information: angela.demichele@uphs.upenn.edu
Key words: Recurrence, disseminated tumor cells, dormancy, minimal residual disease, autophagy, mTOR, Everolimus, hydroxychloroquine
Citation Format: Bayne LJ, Nivar I, Goodspeed B, Wileyto P, Savage J, Shih NNC, Feldman MD, Edwards J, Clark AS, Fox KR, Matro JM, Domchek SM, Bradbury AR, Shah PD, Chislock EM, Belka GK, Wang J, Amaravadi R, Chodosh LA, DeMichele AM. Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-07-09.
Collapse
Affiliation(s)
- LJ Bayne
- University of Pennsylvania, Philadelphia, PA
| | - I Nivar
- University of Pennsylvania, Philadelphia, PA
| | - B Goodspeed
- University of Pennsylvania, Philadelphia, PA
| | - P Wileyto
- University of Pennsylvania, Philadelphia, PA
| | - J Savage
- University of Pennsylvania, Philadelphia, PA
| | - NNC Shih
- University of Pennsylvania, Philadelphia, PA
| | - MD Feldman
- University of Pennsylvania, Philadelphia, PA
| | - J Edwards
- University of Pennsylvania, Philadelphia, PA
| | - AS Clark
- University of Pennsylvania, Philadelphia, PA
| | - KR Fox
- University of Pennsylvania, Philadelphia, PA
| | - JM Matro
- University of Pennsylvania, Philadelphia, PA
| | - SM Domchek
- University of Pennsylvania, Philadelphia, PA
| | - AR Bradbury
- University of Pennsylvania, Philadelphia, PA
| | - PD Shah
- University of Pennsylvania, Philadelphia, PA
| | - EM Chislock
- University of Pennsylvania, Philadelphia, PA
| | - GK Belka
- University of Pennsylvania, Philadelphia, PA
| | - J Wang
- University of Pennsylvania, Philadelphia, PA
| | - R Amaravadi
- University of Pennsylvania, Philadelphia, PA
| | - LA Chodosh
- University of Pennsylvania, Philadelphia, PA
| | | |
Collapse
|
3
|
Shah PD, Digiovanni L, Maxwell KN, Bradbury AR, Van Den Akker J, Kim S, Gil E, Simon MS, Nathanson KL, Domchek SM. Abstract P5-10-04: Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Few reports describe the spectrum of mutations in breast and ovarian cancer predisposition genes found specifically in African Americans. Methods: 560 women who self-identified as African American (AA) from the University of Pennsylvania and Wayne State University were included in this IRB-approved, case-control study. Cases (n=218 with a personal history of breast and/or ovarian cancer) and controls (n=342 without breast or ovarian cancer) underwent germline genetic testing using the Color Genomics 19-gene breast and ovarian cancer risk panel. The subset of AA patients diagnosed with breast cancer ≤40 (n=185) was compared to an institutional cohort of white patients with breast cancer diagnosed ≤40 (n=189). Results: Of 218 AA cases, 70 had pathogenic or likely pathogenic (P/LP) mutations (BRCA1: n=36; BRCA2: n=24; TP53: n=3; RAD51D: n=2; ATM: n=2; CHEK2: n=2 and MSH6: n=1). Forty-two of 218 patients (19%) had at least one variant of uncertain significance (VUS). Of 342 AA controls, 5 women had P mutations in 5 distinct genes: BRCA2, ATM, BRIP1, PALB2 and PMS2. 55 control patients (16%) had at least one VUS. Many of the 75 P/LP mutations (cases, 70 mutations; controls, 5 mutations) in the full AA cohort were unique variants. In the 135 patients who had BRCA1/BRCA2 sequencing prior to testing under this protocol, the Color Genomics platform identified all 56 pathogenic mutations. Among AA patients diagnosed with breast cancer ≤40 (n=185), the incidence of TP53 and ATM pathogenic mutations was similar to the white, early-onset breast cancer cohort (n=189): TP53, 1% in both cohorts; ATM = 1% in AA patients and 2% in whites. However, no patients in the AA, early-onset cohort had germline CHEK2 mutations, compared to 4% of white, early-onset breast cancer patients (p=0.007). Conclusions: Taken together, the results of this study demonstrate the importance of considering germline mutation testing in the AA population. Examination of mutations and disease phenotypes within the AA population may facilitate understanding of the clinical risk associated with variants of uncertain significance. Further comparative data between the AA and white cohorts will be presented.
Citation Format: Shah PD, Digiovanni L, Maxwell KN, Bradbury AR, Van Den Akker J, Kim S, Gil E, Simon MS, Nathanson KL, Domchek SM. Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-10-04.
Collapse
Affiliation(s)
- PD Shah
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - L Digiovanni
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - KN Maxwell
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - AR Bradbury
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - J Van Den Akker
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - S Kim
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - E Gil
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - MS Simon
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - KL Nathanson
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - SM Domchek
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Color Genomics, Burlingame, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| |
Collapse
|
4
|
Lynch MC, Mankoff D, Bradbury AR, Domchek S, Glick JH, Matro J, DeMichele A, Clark AS. Abstract P6-01-02: Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Response of bone-only (BO) and bone-dominant (BD) metastatic breast cancer (mBC) to therapy is difficult to assess by conventional imaging. UPCC 17113 is a single institution prospective cohort study evaluating FDG PET at early and conventional follow up intervals, 4 and 12 weeks respectively, in patients with hormone receptor (HR) positive mBC receiving endocrine therapy. The objective of this study is to assess the relationship between changes relative to baseline in standard uptake values (SUV) of specific bone lesions and progression free survival (PFS). We will also explore change in SUV as it relates to overall survival (OS) and skeletal related events (SRE). We present interim results.
Methods: Enrolled patients were ≥18 years with biopsy proven or documented clinically obvious HR-positive BD/BO mBC due to start new endocrine therapy. Any line endocrine therapy was allowed. FDG PET was performed at baseline, 4 and 12 weeks after initiation of new therapy. SUVmax for the 5 most metabolically active osseous lesions, excluding sites previously treated by radiation or surgery, were recorded at baseline, 4- and 12- week time-points. Average index lesion SUVmax (sum SUVmax/#lesions) and % change from baseline were calculated. Decline of ≥30% from baseline was defined as significant.
Results: As of 6/1/2015, 11 patients were enrolled. All patients have completed the 4-week scan and 8 have completed the 12-week scan. Five and 6 out of the 11 patients had BO and BD HR-positive mBC respectively. Detectable changes in SUV from baseline were noted in all patients at both 4 and 12 weeks, with a 37% overall decline in average index lesion SUVmax at 4 weeks. 8 of 11 patients had a ≥30% decline, in SUV at 4 weeks averaging 46%. Five of the 6 patients in this group who completed the 12-week scan had a sustained decline averaging 50% from the baseline. Of note, the average decline between 4 and 12 weeks in this group was only 8%. Despite having an overall decline from baseline of 44%, the sixth patient in this group had an increase between 4 and 12 weeks of 22%. Three of the 11 patients had a <30% decline at 4 weeks with an average decline of 12%. Of the two patients in this group with 12 week scans, both had average increase of 25% from 4 weeks to 12 weeks, and an average overall increase from baseline of 12%.
Conclusions: There are detectable changes in FDG SUV of osseous lesions at 4 and 12 weeks following initiation of endocrine therapy in patients with BO or BD HR positive mBC. Our interim results demonstrate the emergence of 3 groups of patients: (1) those who have a <30% decline at 4 weeks and increase of SUV at 12 weeks, (2) those who have a ≥30% decline in SUV at 4 weeks with sustained decline at 12 weeks, and (3) those who have a ≥30% reduction in SUV at 4 weeks but who do not have a sustained decline at 12 weeks. These interim results suggest that early FDG PET/CT may provide information on mBC response to endocrine therapy and insight into timing of response and progression. As more patients are enrolled and complete the studies, clearer patterns will emerge which will be correlated with PFS, OS and SRE.
Citation Format: Lynch MC, Mankoff D, Bradbury AR, Domchek S, Glick JH, Matro J, DeMichele A, Clark AS. Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-01-02.
Collapse
Affiliation(s)
- MC Lynch
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - D Mankoff
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - AR Bradbury
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - S Domchek
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - JH Glick
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - J Matro
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - A DeMichele
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - AS Clark
- Hospital of the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
5
|
Bradbury AR, Patrick-Miller L, Egleston BE, Maxwell KN, Brandt A, Brower J, DiGiovanni L, Long JM, Powers J, Stopfer J, Nathanson KL, Domchek SM. Abstract P2-09-01: Patient reported outcomes of multiplex breast cancer susceptibility testing utilizing a tiered-binned counseling and informed consent model in BRCA1/2 negative patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The risks, benefits and utilities of multiplex panels for breast cancer susceptibility are unknown and new counseling and informed consent models are needed. We sought to obtain patient reported outcomes of multiplex testing in BRCA1/2 negative patients utilizing a novel, previously piloted tiered-binned counseling model for multiplex testing. Methods:BRCA1/2 negative participants completed pre(V1) and post-test counseling(V2) and surveys evaluating cognitive, affective and behavioral responses to a 25-gene multiplex testing panel. We used linear regressions with estimation by GEE where appropriate. Results:376 patients have been approached. To date, 124 participants(33%) have consented to the study, 21(6%) declined and 231(61%) are considering. Of 95 who have completed pre-test counseling(V1), 88(93%) elected to proceed with 25-gene panel testing and (81%) were classified as making an informed choice after tiered-binned counseling. 6/53(11%) participants received a positive result, including 1 mutation in MSH2 and 5 in moderate penetrance genes (2 ATM, 1 BARD1, 1 CHEK2, 1 PALB2). 22/53(42%) participants received a variant of unknown significance(VUS). General anxiety and perceived utility decreased significantly with pre-test counseling and after results (Table 1). Knowledge increased with pre-test counseling; cancer worry increased after receipt of multiplex results. Higher cancer worry was associated only with lower income (2.6 points/income category, p<0.01). Those with a VUS had greater decreases in perceived utility compared to negative (p=0.01) or positive (p=0.003) results. To date, there are no other significant differences in knowledge, distress or uncertainty by test result. Medical management recommendations for the proband changed in 3/6 with a positive result. Cascade testing in the family was discussed as an option in 3/6 with a positive result. Conclusions:Many BRCA1/2-negative patients proceed with 25-gene cancer susceptibility testing if offered and most make informed choices utilizing a tiered-binned genetic counseling model. The tiered-binned counseling model is associated with increased knowledge, decreases in general anxiety and uncertainty after pre-test counseling and disclosure of results, but an increase in cancer worry after result disclosure. The clinical utility, long-term outcomes and differences in patient reported outcomes by test result remain unknown.
Table 1 Baseline, Mean(SD)After V1, Mean(SD)After V2, Mean(SD) N=75ˆ;N=49ˆˆN=75ˆ;N=49ˆˆN=49ˆˆGeneral Anxiety (range 0-21)6.4(3.9)*;6.9(3.9)**6.0(4.3)*;6.6(4.2)**5.8(4.5)**General Depression (range 0-212.8(2.9);3.1(3.2)3.0(3.5);3.1(3.6)3.0(3.7)State Anxiety (range 20-80)35.5(11.2);36.6(11.9)35.5(11.8);36.8(11.9)36.1(12.2)Cancer Worry (range 0-75)18.2(13.5);20.1(13.8)**16.7(12.5);17.2(11.9)**21.0(13.9)**Knowledge (range 17-82)65.7(5.0)**;66.5(5.0)**68.0(5.7)**;68.4(5.6)**67.3(4.9)**Uncertainty (range 0-15)5.8(3.9);6.2(4.3)5.6(3.7);5.4(3.2)5.6(3.5)Perceived Utility (range 24-120)75.2(14.0)*;75.9(14.0)**73.0(14.1)*;74.1(13.4)**68.4(16.9)***p≤0.05 **p≤0.01. ˆcompleted V1. ˆˆcompleted V1 & V2. To date, 53 have received results and 49 have completed post-disclosure surveys.
Citation Format: Bradbury AR, Patrick-Miller L, Egleston BE, Maxwell KN, Brandt A, Brower J, DiGiovanni L, Long JM, Powers J, Stopfer J, Nathanson KL, Domchek SM. Patient reported outcomes of multiplex breast cancer susceptibility testing utilizing a tiered-binned counseling and informed consent model in BRCA1/2 negative patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-01.
Collapse
Affiliation(s)
- AR Bradbury
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - L Patrick-Miller
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - BE Egleston
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - KN Maxwell
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - A Brandt
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - J Brower
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - L DiGiovanni
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - JM Long
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - J Powers
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - J Stopfer
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - KL Nathanson
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| | - SM Domchek
- University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
6
|
Bradbury AR, Patrick-Miller L, Egleston B, Schwartz L, Tuchman L, Moore C, Rauch P, Sands C, Shorter R, Rowan B, Malhotra S, van Decker S, Schmidheiser H, Sicilia P, Bealin L, Daly M. Abstract P6-08-01: Perceptions of breast cancer risk, psychological adjustment and behaviors in adolescent girls at high-risk and population-risk for breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Preliminary evidence suggests that many girls from breast cancer (BC) families are aware of their increased risk for BC. How this awareness impacts their psychosocial adjustment and health behaviors remains unknown.
METHODS: 11–19 YO girls at high-risk (HR) or population-risk (PR) for BC completed self-administered quantitative surveys informed by the Self-Regulation Theory of Health Behavior. Girls with a first or second-degree relative with BC were classified as HR. For hypothesis testing, we used simple linear and logistic regressions. To account for correlation of responses within families, we used robust (cluster-corrected) standard errors or Generalized Estimating Equations.
RESULTS: 47 PR and 89 HR girls have completed surveys. Age did not differ between groups (Mage = 15.6; SD=2.4). 30% of HR girls have a mother with BC. 67% of HR girls vs. 30% of PR girls reported self-perceived risk for adult BC to be “higher than other girls my age,” (p = <0.01, Table 1).
Perceived risk was associated with an increasing number of first and second-degree relatives with BC (p = 0.002) and older age (p = 0.01). There was no evidence that the relationship between perceived risk and age was moderated by risk status (p = 0.740 for interaction terms). The majority of both HR and PR girls reported that there are things women and girls their age can do to prevent BC. (table 1) Perceived controllability of BC did not differ significantly by age or risk status. HR girls reported higher general anxiety (p = 0.07), but not depression than PR girls. HR girls more frequently reported tobacco use than PR girls (p = 0.05). HR girls also reported greater alcohol use, more frequent performance of self-breast exams and less frequent physical activity than PR girls, although these differences were not significant.
CONCLUSION: Girls from BC families are more likely to perceive themselves to be at increased risk for BC, to experience more general anxiety, and to have engaged more frequently in risk behaviors, particularly tobacco use. The majority of girls perceive BC to be preventable both for women in general and for themselves, suggesting a potential “teachable moment” among adolescents that might be sustainable across the lifespan. Further research evaluating knowledge and perceptions of breast cancer risk throughout adolescent development and differences among subgroups could inform strategies to optimize adolescent psychosocial responses to hereditary cancer risk and promote preventive health behaviors among both HR and PR girls.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-08-01.
Collapse
Affiliation(s)
- AR Bradbury
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Patrick-Miller
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - B Egleston
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Schwartz
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Tuchman
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - C Moore
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - P Rauch
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - C Sands
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - R Shorter
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - B Rowan
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - S Malhotra
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - S van Decker
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - H Schmidheiser
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - P Sicilia
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Bealin
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - M Daly
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
7
|
Patrick-Miller LJ, Bradbury AR, Pius R, Wroblewski K, Verp MS, Jackson S, Gulden C, Newstead G, Abe H, Olopade OI. Results from a longitudinal breast MRI surveillance study: Psychological impact for high-risk women. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Bradbury AR, Patrick-Miller LJ, Tuchman L, Moore C, Rauch P, Sands CB, Shorter R, Rowan B, Malhotra S, Van Decker S, Bealin L, Schmidheiser H, Daly MB. Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Bradbury AR, Patrick-Miller L, Fetzer D, Egleston B, Cummings SA, Forman A, Bealin L, Peterson C, Corbman M, O'Connell J, Daly MB. Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results. Clin Genet 2010; 79:125-31. [PMID: 21039431 DOI: 10.1111/j.1399-0004.2010.01540.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BRCA1/2 test disclosure has, historically, been conducted in-person by genetics professionals. Given increasing demand for, and access to, genetic testing, interest in telephone and Internet genetic services, including disclosure of test results, has increased. Semi-structured interviews with genetic counselors were conducted to determine interest in, and experiences with telephone disclosure of BRCA1/2 test results. Descriptive data are summarized with response proportions. One hundred and ninety-four genetic counselors completed self-administered surveys via the web. Although 98% had provided BRCA1/2 results by telephone, 77% had never provided pre-test counseling by telephone. Genetic counselors reported perceived advantages and disadvantages to telephone disclosure. Thirty-two percent of participants described experiences that made them question this practice. Genetic counselors more frequently reported discomfort with telephone disclosure of a positive result or variant of uncertain significance (p < 0.01) than other results. Overall, 73% of participants reported interest in telephone disclosure. Many genetic counselors have provided telephone disclosure, however, most, infrequently. Genetic counselors identify potential advantages and disadvantages to telephone disclosure, and recognize the potential for testing and patient factors to impact patient outcomes. Further research evaluating the impact of testing and patient factors on cognitive, affective, social and behavioral outcomes of alternative models of communicating genetic information is warranted.
Collapse
Affiliation(s)
- A R Bradbury
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Patrick-Miller LJ, Egleston B, Olopade OI, Daly MB, Daugherty C, Sands CB, Schmidheiser H, Gulden C, Pawlowski K, Bradbury AR. Predictors of BRCA-positive parents' disclosure of cancer risk and risk reduction options to offspring. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Bradbury AR, Patrick-Miller LJ, Tuchman L, Moore C, Rauch P, Sands CB, Schmidheiser H, Daly MB. Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Bradbury AR, Patrick-Miller L, Egleston B, Sands C, Feigon M, Pawlowski K, Ibe C, Daly M, Olopade O, Daugherty C. Parent perceptions of offspring responses to parental communication of BRCA1/2 test results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1511] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1511 Background: Many BRCA1/2 mutation carriers report sharing their genetic test results with their minor children. The impact of this communication on offspring remains unknown. Methods: 163 parents who had BRCA1/2 testing completed qualitative interviews regarding their experiences with communication of their genetic test results to offspring. Descriptive responses were coded and response proportions utilized to summarize results. We used multiple regressions fit by GEE to test associations with disclosure. We controlled for parent mutation status in each regression. Results: 163 parents (52 BRCA1/2 mutation carriers) reported on 323 offspring 5 to 25 years old at the time of parent genetic testing. 107 (66%) parents reported disclosing to at least one offspring. Child age (p < 0.001) and parent cancer history (p = 0.004) were positively associated with disclosure. Parents without a BRCA1/2 mutation were more likely to communicate test results than parents with a mutation (p = 0.007). Among parents who disclosed, few (14%) reported they perceived their offspring to have had an initial negative affective or behavioral response. Others (13%) reported offspring concern for self and family. Reports of initial negative responses and concern were more frequent among parents with a mutation or a variant of uncertain significance. Many parents reported that the communication had no significant impact (39%) or a positive impact (36%) on their offspring. Conclusions: Many parents report sharing BRCA1/2 test results with their offspring. Parent self-reports suggest that they do not perceive most offspring to experience adverse reactions to this communication. Self-reports suggest that offspring learning of a BRCA1/2 mutation or a variant of uncertain significance may be more susceptible to initial negative reactions. Further research is necessary to explore psychosocial and behavioral responses to learning of hereditary risk during childhood and adolescence, and to inform the development of interventions to optimize adaptive response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. R. Bradbury
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - L. Patrick-Miller
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - B. Egleston
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - C. Sands
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - M. Feigon
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - K. Pawlowski
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - C. Ibe
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - M. Daly
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - O. Olopade
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| | - C. Daugherty
- Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago, Chicago, IL
| |
Collapse
|
13
|
Bradbury AR, Patrick-Miller L, Cummings SA, Fetzer D, Daly M. Telephone disclosure of BRCA1/2 test results: a survey of genetic counselors. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1098
Disclosure of BRCA1/2 test results has historically been conducted in person by a certified genetic counselor (GC) and/or other health care professional. Due to increasing demand for and access to BRCA1/2 testing, there has been interest in providing genetic counseling services, including disclosure of test results, by telephone and internet. The practice of telephone disclosure among certified genetic counselors has not been described. We conducted semi-structured interviews with GCs to determine current prevalence of, and future interest in, telephone disclosure (TD) of BRCA1/2 test results. Surveys were self-administered and completed via a secure web site. Participants were recruited through the NSGC Cancer Special Interest Group. 195 GCs completed the survey (25% response rate). 23% of respondents have provided pre-test counseling by telephone. 98% reported having provided genetic test results by telephone, although many (48%) conduct TD rarely (<25% of the time). 33% reported TD experiences that had made them question TD as a practice. Comfort with TD varied by test result (37% comfortable with TD for positive test results, 77% for true negative results, 49% for indeterminate results and 33% for VUS results). The majority of GCs do not include a physician (85%) in the TD. Many report encouraging in-person follow-up with a GC (44%) and/or physician (30%). Overall, 42% reported being very interested in TD and 73% felt TD could be an acceptable standard practice. These results suggest many genetic counselors have provided genetic test results by phone and are interested in including telephone disclosure of BRCA1/2 test results in their practice. Given provider interest and the expansion of testing for BRCA1/2 and other hereditary cancer syndromes, further research evaluating the cognitive, affective and behavioral responses to telephone disclosure is warranted. Understanding the impact of telephone disclosure on factors such as, comprehension, risk perception, communication and performance of risk reducing behaviors and their mediators will be critical for the development of telephone disclosure policy and procedures that will optimize adaptive responses to receiving genetic test results via telephone or internet.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1098.
Collapse
Affiliation(s)
- AR Bradbury
- 1 Population Science, Fox Chase Cancer Center, Philadelphia, PA
| | | | - SA Cummings
- 3 Myriad Genetic Laboratories, Inc., Salt Lake City, UT
| | - D Fetzer
- 1 Population Science, Fox Chase Cancer Center, Philadelphia, PA
| | - M Daly
- 1 Population Science, Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
14
|
Bradbury AR, Patrick-Miller L, Feigon M, Pawlowski K, Egleston B, Ibe C, Sands CB, Cummings S, Olopade OI, Daugherty CK. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of parents who completed BRCA1/2 testing. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Shen W, Ross LF, Patrick-Miller L, Olopade OI, Cummings SA, White MA, Dudlicek L, Bradbury AR. Tobacco use among individuals presenting for cancer risk assessment. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1547 Background: An important component of cancer risk assessment (CRA) is the evaluation of exposures and preventive health behaviors. Tobacco use (TU) remains a significant contributor to cancer risk and decreasing tobacco use is a major national health objective. Methods: Clinical charts were reviewed to evaluate the incidence of TU and characteristics of tobacco users (TUs) among individuals presenting to the University of Chicago Cancer Risk Clinic for cancer risk assessment (CRA). Results: Among 98 individuals (97% female) presenting for CRA from 12/05–10/06, 51% (50/98) reported no TU, 38% (37/98) reported prior TU and 11% (11/98) reported current TU. Current tobacco users included 10% (7/73) of whites and 18% (4/22) of blacks with no TU among other racial groups (0/3). 45% of TUs (5/11) had a personal history of cancer. 45% of TUs reported compliance with self-breast examination, 73% with cervical cancer screening. Among TUs over 40 years old (YO), 67% (6/9) reported a mammogram in the last year and the 2 TUs over 50 YO reported a screening colonoscopy. All TUs reported interest in tobacco cessation interventions. Conclusions: Tobacco use among individuals presenting for CRA is lower than reported general population rates of TU (23%). Despite this, a proportion of individuals presenting for CRA report current TU, despite engaging in other cancer prevention behaviors. Continued review of clinical encounters from 2004- 06 (n=425) will allow for multi-variate analysis of predictors of current TU, which will inform future research employing cancer risk assessment encounters as “teachable moments” to optimize tobacco cessation outcomes. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. Shen
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. F. Ross
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Patrick-Miller
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - O. I. Olopade
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - S. A. Cummings
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - M. A. White
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Dudlicek
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - A. R. Bradbury
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| |
Collapse
|
16
|
Bradbury AR, Cummings SA, Dignam JJ, Patrick-Miller L, Verp M, White MA, Dudlicek L, Newstead G, Abe H, Schmidt R, Olopade OI. Health-related quality of life among high-risk women in an MRI surveillance study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1522 Background: The quality of life (QOL) and psychological impact of incorporating MRI into breast cancer screening programs for high-risk women (HRW) has not been well studied. Psychological and biological risk factors, e.g. cancer history, BRCA mutation, imaging recall, generalized anxiety or clinical depression may mediate QOL outcomes. Methods: 100 HRW undergoing intensive surveillance including yearly mammography, semiannual breast ultrasound and breast MRI have completed QOL (SF-36), anxiety (STAI) and depression (Beck) questionnaires at semi-annual visits. 56 HRW have completed 3 screenings. Differences in QOL measures over time were evaluated using longitudinal regression models. Differences between participants and population norms (PN), women with/without a history of cancer and with/without a BRCA mutation were assessed using t-tests. Results: QOL scores increased over time and were statistically significant for the general health (GH) subscale (p=0.016). All QOL subscales were higher than PN at baseline and were significantly higher than PN at 12 months. Mean GH score at 12 months = 80.0, PN 72.7 (SD14.2, p<0.01). Mean mental health score at 12 months = 78.9, PN 73.4 (SD14.9, p<0.01). At baseline, BRCA carriers had lower QOL scores than non-carriers and women with a history of cancer had higher QOL scores than unaffected participants, although these differences were not statistically significant. Conclusions: These data suggest that intensive breast cancer screening incorporating breast MRI may have a positive effect among HRW. Continued enrollment will allow for multi-variate characterization of psychological and biological predictors of change in QOL and psychological well-being among high-risk women undergoing intensive screening. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. R. Bradbury
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - S. A. Cummings
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - J. J. Dignam
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Patrick-Miller
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - M. Verp
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - M. A. White
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Dudlicek
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - G. Newstead
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - H. Abe
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - R. Schmidt
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - O. I. Olopade
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| |
Collapse
|
17
|
Pawlowski K, Patrick-Miller L, Daugherty CK, Olopade OI, Dignam JJ, Ibe CN, Hlubocky FJ, Cummings SA, White MA, Dudlicek L, Bradbury AR. Content and method of parental disclosure of genetic risk to young adult and minor children in BRCA families. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1536 Background: Prior research has found that many BRCA mutation carriers report discussing their genetic test results with their minor children. The content, method and process of this communication have not been previously described. Methods: 20 parents (yielding 42 parent-offspring pairs, POP) have completed a 62-item questionnaire regarding the content and methods of communication of genetic risk to offspring. Results: Of 19 (45%) POP where parents reported disclosure of their BRCA mutation to offspring in response to a binary (yes/no) question, all reported telling their children about the genetic mutation itself, as well as the parents’ risk for cancer. In 74% of POP the offspring’s chance of inheriting the mutation or risk for cancer were said to have been communicated. In 53% of POP parents reported discussion of parental risk reduction measures, and in only 37% of POP parents reported communication of offspring risk reduction measures. Of the POP where parents reported some communication of cancer risk, 22% described incorporating written materials. In 75% of POP parents reported communication through multiple conversations over time (1 -20 conversations, up to 4 years). Conclusions: Although many BRCA carriers report discussing their genetic mutation with offspring, the content and extent of parental communication is variable, often including information regarding the genetic mutation, but less frequently the offspring’s risk of inheriting the gene and infrequently communication regarding risk reduction measures. Further research on this expanding cohort will allow for analyses of parent and child factors associated with disclosure content in order to guide the development of interventions to facilitate age and content-appropriate communication of genetic risk to at-risk offspring. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Pawlowski
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Patrick-Miller
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - C. K. Daugherty
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - O. I. Olopade
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - J. J. Dignam
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - C. N. Ibe
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - F. J. Hlubocky
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - S. A. Cummings
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - M. A. White
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - L. Dudlicek
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| | - A. R. Bradbury
- University of Chicago, Chicago, IL; The Cancer Institute of New Jersey, New Brunswick, NJ
| |
Collapse
|
18
|
Bradbury AR, Daugherty CK, Dignam J, Ibe C, Auh S, Fay H, Cummings SA, White MA, Olopade OI. Disclosure patterns and decision making preferences in BRCA 1/2 mutation carriers with young adult and minor children. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1015 Background: Genetic testing of minors for adult-onset diseases has generally been discouraged. Yet, limited data suggests that many BRCA mutation carriers discuss their test results with their minor children. How parents make the decision to share this information and the effects on their health, their child and the family remains unknown. Methods: We sought to evaluate disclosure patterns and decision making practices among BRCA1/2 mutation carriers with children under the age of 25. 42 parents (with 86 children) completed a semi-structured telephone interview regarding communication of their genetic test results to their children. Chi-squared tests to assess associations between parent/child characteristics and disclosure were computed using robust variance estimates to account for clustering by family unit. Results: 55% of parents discussed hereditary risk of cancer and/or their genetic test results with at least one child. Factors associated with disclosure included older child age (p<0.001), female parent gender (p=0.049), parent history of prophylactic surgery (mastectomy: p = 0.021, oophorectomy: p<0.001) and education limited to high school (p=0.085). Child gender and parent’s history of cancer were not significantly associated with disclosure. Most participants reported themselves (45%) or their spouse (40%) as the most important person in the decision to disclose. Reports of physician (14%) and genetic counselor (21%) involvement were low. Conclusions: Parental decisions to disclose BRCA test results to children are complex and may reflect differences in perceptions of genetic disease. Further research is needed to understand parental motivations for disclosure and to define a role for health care professionals to improve counseling and recommendations regarding the risks and benefits of early communication of genetic risk to children. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | - C. Ibe
- University of Chicago, Chicago, IL
| | - S. Auh
- University of Chicago, Chicago, IL
| | - H. Fay
- University of Chicago, Chicago, IL
| | | | | | | |
Collapse
|
19
|
Bradbury AR, Daugherty CK, Auh S, Hlubocky FJ, Cummings S, White M, Olopade OI. Parental disclosure of genetic test results to young adults, adolescents and children. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - S. Auh
- Univ of Chicago Hospitals, Chicago, IL
| | | | | | - M. White
- Univ of Chicago Hospitals, Chicago, IL
| | | |
Collapse
|
20
|
Bradbury AR, Cummings SA, Olopade OI. Prophylactic oophorectomy in BRCA1/2 carriers. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Abstract
The inevitable computerization of medical records may be a boon or a hindrance to the practice of medicine. A comprehensive view of the project is essential for its success. Definite goals for the computerized medical record are stated to this end. An argument is presented for keeping the structure of the medical record separate from any specific requirements of technology. An elegant structure for medical records is proposed, independent of any computer system and requiring a minimum of definitions or special characters. The roles of clinical specialists (such as physicians and nurses), medical records specialists, administrators, accountants, and computer architects (hardware and software) are defined. In particular, the tasks of lexicon and template creation are defined and emphasized as urgent and ongoing challenges for specialty organizations.
Collapse
Affiliation(s)
- A R Bradbury
- USAF Hospital Altus/SGHF, Altus AFB, OK 73523-5300
| |
Collapse
|